Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Sylentis
SylentisSpain - Madrid
1 program
1
SYL18001 sodium Low dose q.dPhase 11 trial
Active Trials
NCT04782271CompletedEst. Dec 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SylentisSYL18001 sodium Low dose q.d

Clinical Trials (1)

NCT04782271SylentisSYL18001 sodium Low dose q.d

Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops

Start: Mar 2021Est. completion: Dec 2021
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space